Dermavita Company v EUIPO - Allergan Holdings France (JUVEDERM VOLITE) (EU trade mark - Judgment) [2021] EUECJ T-637/20 (06 October 2021)

Dermavita Company v EUIPO - Allergan Holdings France (JUVEDERM VOLITE) (EU trade mark - Judgment) [2021] EUECJ T-637/20 (06 October 2021)

The Board of Appeal correctly held that it was not competent to grant an extension of the time limit under Article 101(4) of Regulation 2017/1001, as this competence lies solely with the Executive Director, who did not extend the relevant time limits. The applicant did not apply for restitutio in integrum, which was...

Source-derived case information.

Citation
[2021] EUECJ T-637/20
Parties
Applicant: Dermavita Company S.a.r.l.; Respondent: European Union Intellectual Property Office (EUIPO); Other Party to Proceedings Before Board of Appeal: Allergan Holdings France SAS
Jurisdiction
European Union
Procedural Posture
EU Trade Mark Invalidity Appeal / Judgment on Action Against Board of Appeal Decision
Outcome
Action dismissed
Legal Topics
EU Trade Mark Law, Time Limits, Exceptional Occurrences, Restitutio in Integrum, Interruption of Proceedings, COVID 19 Pandemic, Capital Controls
Intellectual Property Administrative Law EU Trade Mark Law Time Limits Exceptional Occurrences Restitutio in Integrum Interruption of Proceedings COVID 19 Pandemic +1 more

Source-derived case record

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Downloadable case file Legal principles 4 Authorities cited 6 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Parties

Dermavita Company S.a.r.l.

Applicant

European Union Intellectual Property Office (EUIPO)

Respondent

Allergan Holdings France SAS

Other Party to Proceedings Before Board of Appeal

Procedural Posture

EU Trade Mark Invalidity Appeal / Judgment on Action Against Board of Appeal Decision

  1. 1 Whether the Board of Appeal erred in not granting an extension of time under Article 101(4) of Regulation 2017/1001 due to COVID-19 and related circumstances.
  2. 2 Whether the Board of Appeal erred in not interrupting proceedings under Article 106(1)(b) of Regulation 2017/1001 due to Lebanese capital controls.

Ratio Decidendi

The Board of Appeal correctly held that it was not competent to grant an extension of the time limit under Article 101(4) of Regulation 2017/1001, as this competence lies solely with the Executive Director, who did not extend the relevant time limits. The applicant did not apply for restitutio in integrum, which was the appropriate remedy for late payment of the appeal fee. Article 106(1)(b) does not apply to applicants for invalidity, and general capital controls do not qualify as action against property under that provision. Accordingly, the action was dismissed.

Court Disposition

Action dismissed

Orders

  • Dismisses the action
  • Orders Dermavita Company S.a.r.l. to pay the costs